Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.50 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.50 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532405 | 0.82 | ALDH1A1 (0.54) | DHODHKMT2A | |
| SCHEMBL1969326 | 0.80 | DHODH (0.51) | PIN1DCLRE1BPTGER4DHODHNPC1 | |
| SCHEMBL9355817 | 0.77 | GABRP (0.48) | SORT1ACLYKMT2APTGS1 | |
| SCHEMBL10024224 | 0.75 | DCLRE1B (0.61) | PIN1DCLRE1BPTGER4GRM5ACLY | |
| SCHEMBL5092896 | 0.75 | PTGS1 (0.41) | PIN1GRM5MDM2PTGS1PTGS2 | |
| SCHEMBL8946347 | 0.74 | MEN1 (0.64) | NPC1RAB9AL3MBTL1KMOKMT2A | |
| SCHEMBL14152580 | 0.73 | CNR2 (0.61) | PIN1PTGER4DHODHKMOMDM2 | |
| SCHEMBL8946514 | 0.73 | KMT2A (0.54) | SORT1DHODHKMT2A | |
| SCHEMBL25510516 | 0.73 | KDM5B (0.42) | GRM5PTGS1PTGS2 | |
| SCHEMBL3787844 | 0.73 | PDE4B (0.59) | NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323570-B2 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES (US) | 2008-01-29 | — | — | US | disclosed |
| US-7211595-B2 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES (US) | 2007-05-01 | — | — | US | disclosed |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | ABBVIE INC. | 2006-11-23 | — | — | US | disclosed |
| EP-1339695-B1 | FARNESYLTRANSFERASE INHIBITORS | ABBOTT LAB (US) | 2006-04-19 | — | — | EP | disclosed |
| CN-1487924-A | Farnesyl transferase inhibitors | ���Ͽع�����˾ | 2004-04-07 | — | — | CN | disclosed |
| US-20030087940-A1 | Farnesyltransferase inhibitors | ABBVIE INC. | 2003-05-08 | — | — | US | disclosed |
| US-20020115640-A1 | Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents | ABBOTT LABORATORIES | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115640-A1 | Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents | FNTB, FNTA, ACAT2 | PIN1 1829/4885SORT1 4594/4885DCLRE1B 688/4885 |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | FNTB, FNTA, FDPS | PIN1 1042/4885SORT1 4567/4885DCLRE1B 407/4885 |
| US-20030087940-A1 | Farnesyltransferase inhibitors | FNTB, FNTA, FDPS | PIN1 1214/4885SORT1 4529/4885DCLRE1B 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.